UBS Group
UROV

UBS Group’s Urovant Sciences Ltd. UROV Stock Holding History

UBS Group’s Portfolio UROV Stock Details UROV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-329
Closed -$3K – 8690
2020
Q2 		$3K Buy
+329
New +$3.16K ﹤0.01% 7592
2020
Q1 		– Sell
-1,591
Closed -$25K – 8666
2019
Q4 		$25K Sell
1,591
-1,547
-49% -$16.8K ﹤0.01% 6761
2019
Q3 		$30K Buy
+3,138
New +$27.2K ﹤0.01% 6499
2019
Q2 		– Sell
-850
Closed -$9K – 8336
2019
Q1 		$9K Buy
+850
New +$8.72K ﹤0.01% 6907

Other funds holding UROV

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
Pekin Hardy Strauss Chicago, Illinois $957M AUM 44.61% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group's UROV Position: Q3 2020 in Review

UBS Group sold out of Urovant Sciences Ltd. (UROV) in Q3 2020, closing a stake of 329 shares — an estimated $3K sold.

UBS Group first reported a position in UROV in Q1 2019 and held it in 4 quarters. The position peaked at $30K in Q3 2019. 23 funds tracked by Wall St. Rank hold UROV as of Q3 2020.

  • UBS Group reported no remaining Urovant Sciences Ltd. position as of Q3 2020 after selling out during the quarter.
  • UBS Group sold 329 Urovant Sciences Ltd. shares in Q3 2020, an estimated $3K.
  • UBS Group first reported a position in Urovant Sciences Ltd. in Q1 2019 and held it in 4 quarters.
  • UBS Group's Urovant Sciences Ltd. position peaked at $30K in Q3 2019.
  • 23 funds tracked by Wall St. Rank held Urovant Sciences Ltd. as of Q3 2020.

Based on UBS Group's 13F filing for Q3 2020, filed 12 Nov 2020.